Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

Prior treatment

• Any previous treatment of the pancreatic cancer except biliary short metal stenting (chemotherapy, targeted tumor therapy, local ablative therapy, previous irradiation within the actual fields of planned radiotherapy)
• Contraindication for pancreas resection
• Participation in any other clinical trial or treatment with any experimental drug within 28 days before enrolment to the study or during study participation until the end of treatment visit that can be interfering with the objectives of the study
• Previous or concurrent malignant tumor disease other than underlying tumor disease (with the exception of cervical cancer in situ, adequately treated non-melanoma skin cancers, superficial bladder tumors (Ta, Tis, and T1) or any curatively treated without chemotherapy and favourable prognosis tumors without evidence of disease for \> 3 years prior to enrolment)
• Any severe and/or uncontrolled medical conditions including but not limited to:
  • Clinically significant cardiovascular or vascular disease : angina pectoris (even controlled), previous myocardial infarction, serious uncontrolled cardiac arrhythmia, chronic heart failure, acute or chronic infectious disease requiring general treatment)
  • Acute and chronic, active infectious disorders that requires systemic treatment
  • Peripheral polyneuropathy \> grade 1
  • Any previous inflammatory disease of colon or rectum
  • Any other severe concomitant disease or disorder, which could influence patient's ability to participate in the study and his/her safety during the study e.g. severe hepatic, renal, pulmonary, metabolic, or psychiatric disorders

Other illness

• Evidence of extent of pancreatic cancer beyond that defined as "borderline resectable" : suspicious lymphadenopathy outside of the standard field of resection (i.e., aortocaval nodes, distant abdominal nodes)
• Patients with known Gilbert's Syndrome or homozygosity for UGT1A1\*28 polymorphism
• Hypersensitivity against any of the study drugs (gemcitabine, oxaliplatin, irinotecan, 5-fluorouracil, folinic acid), or the ingredients of these drugs (e.g. fructose).

Other

• Evidence of distant metastases including ascites
• Pregnant or breast feeding females
• Uracilemia ≥ 16ng/mL either a partial or complete deficiency in dihydropyrimidine dehydrogenase (DPD)
• Uncorrected disturbed electrolyte balance, in particular hypokalemia or hypocalcemia

• ECOG performance status 0 or 1
• Adult patients ≥ 18 years and ≤ 75 years of age
• Histologic or cytologic proven adenocarcinoma of the pancreas (histologic confirmation of diagnosis is preferred)
• Confirmation by independent multidisciplinary expert review of borderline resectable status, according to NCCN-Clinical Practice Guidelines in Oncology "pancreatic adenocarcinoma", version 1.2015.
• Adequate hematologic function, as follows:
• absolute neutrophil count (ANC) ≥ \> 2000/mm3
• platelet count ≥ 100 000/mm3
• haemoglobin ≥ 10 g/dL
• Adequate renal, hepatic and bone marrow function, defined as:
  • Calculated creatinine clearance ≥ 50 mL/min according to MDRD formula
  • Serum total bilirubin ≤ 1.5 times the institutional upper limit of normal. Patients with a biliary short metal stent due to cancer obstruction may be included provided that high-quality imaging is performed before stenting and bilirubin level after stent insertion decreased to ≤ 20 mg/L (≤ 34 µmol/l), and there is no cholangitis.
• Male and female subjects who agree to use highly effective methods of birth control (e.g., condoms, combined oral contraceptives, some intrauterine devices \[IUDs\], sexual abstinence, or sterilized partner)
  • for male subject: during the treatment and for up to 6 months after the last dose of oxaliplatin or up to 3 months after the last dose of irinotcan.
  • for female subject: during the treatment and for up to 4 months after the last dose of oxaliplatin or up to 3 months after the last dose of irinotcan.
• Ability to provide written informed consent before the start of any study specific procedures
• Patient's legal capacity to consent to study participation and to understand and comply with the requirements of the study.